Thermo Fisher Scientific Inc.: Form 10-Q for the period ended Jun 30, 2018
Filed with the SEC on Aug 3, 2018 and accepted by EDGAR at Aug 3, 2018, 11:40 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2018-04-01 to 2018-06-30 | $6.08bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2018-01-01 to 2018-06-30 | $11.93bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2018-04-01 to 2018-06-30 | $242.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2018-01-01 to 2018-06-30 | $476.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2018-04-01 to 2018-06-30 | $1.54bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2018-01-01 to 2018-06-30 | $3.06bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2018-04-01 to 2018-06-30 | $937.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2018-01-01 to 2018-06-30 | $1.72bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2018-04-01 to 2018-06-30 | $170.0m | us-gaap:InterestExpense |
| Interest expense | 6 months2018-01-01 to 2018-06-30 | $333.0m | us-gaap:InterestExpense |
| Income tax | 3 months2018-04-01 to 2018-06-30 | $54.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2018-01-01 to 2018-06-30 | $109.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2018-04-01 to 2018-06-30 | $752.0m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 6 months2018-01-01 to 2018-06-30 | $1.33bn | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2018-04-01 to 2018-06-30 | $1.85 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2018-01-01 to 2018-06-30 | $3.28 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2018-04-01 to 2018-06-30 | $1.87 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2018-01-01 to 2018-06-30 | $3.31 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2018-04-01 to 2018-06-30 | 406,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2018-01-01 to 2018-06-30 | 406,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2018-01-01 to 2018-06-30 | $1.52bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2018-01-01 to 2018-06-30 | $301.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months2018-01-01 to 2018-06-30 | $129.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 6 months2018-01-01 to 2018-06-30 | $0 | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2018-06-30 | $937.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-06-30 | $9.47bn | us-gaap:AssetsCurrent |
| Total assets | At period end2018-06-30 | $55.40bn | us-gaap:Assets |
| Current liabilities | At period end2018-06-30 | $5.98bn | us-gaap:LiabilitiesCurrent |
| Current portion of debt | At period end2018-06-30 | $1.71bn | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2018-06-30 | $26.45bn | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2018-06-30 | 402,796,251 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000097745-18-000029. Last ingested by Listed: Nov 14, 2026, 12:05 ET. Listed shows no prices and gives no investment advice.